BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38520914)

  • 1. Combined SET7/9 and CDK4 inhibition act synergistically against osteosarcoma.
    Shi Y; Wang Z; Shao Y; Guang Q; Zhang J; Liu B; Wu C; Wang Y; Sui P
    Biochem Biophys Res Commun; 2024 May; 708():149808. PubMed ID: 38520914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma.
    Zhou Y; Shen JK; Yu Z; Hornicek FJ; Kan Q; Duan Z
    Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1573-1582. PubMed ID: 29452249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6-Cyclin D-Rb pathway.
    Wang D; Bao H
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):31-40. PubMed ID: 34655298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered G1 phase regulation in osteosarcoma.
    Benassi MS; Molendini L; Gamberi G; Sollazzo MR; Ragazzini P; Merli M; Magagnoli G; Sangiorgi L; Bacchini P; Bertoni F; Picci P
    Int J Cancer; 1997 Oct; 74(5):518-22. PubMed ID: 9355974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
    Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
    Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression.
    Grillo M; Bott MJ; Khandke N; McGinnis JP; Miranda M; Meyyappan M; Rosfjord EC; Rabindran SK
    Breast Cancer Res Treat; 2006 Jan; 95(2):185-94. PubMed ID: 16319987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of G1 phase regulators in MG-63 osteosarcoma cell line.
    Merli M; Benassi MS; Gamberi G; Ragazzini P; Sollazzo MR; Molendini L; Magagnoli G; Ferrari C; Maltarello MC; Picci P
    Int J Oncol; 1999 Jun; 14(6):1117-21. PubMed ID: 10339667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ara-c induces cell cycle G1/S arrest by inducing upregulation of the INK4 family gene or directly inhibiting the formation of the cell cycle-dependent complex CDK4/cyclin D1.
    Sun F; Li N; Tong X; Zeng J; He S; Gai T; Bai Y; Liu L; Lu K; Shen J; Han M; Lu C; Dai F
    Cell Cycle; 2019 Sep; 18(18):2293-2306. PubMed ID: 31322047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitex rotundifolia Fruit Suppresses the Proliferation of Human Colorectal Cancer Cells through Down-regulation of Cyclin D1 and CDK4 via Proteasomal-Dependent Degradation and Transcriptional Inhibition.
    Song HM; Park GH; Park SB; Kim HS; Son HJ; Um Y; Jeong JB
    Am J Chin Med; 2018; 46(1):191-207. PubMed ID: 29298515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphorylation of p27Kip1 regulates assembly and activation of cyclin D1-Cdk4.
    Larrea MD; Liang J; Da Silva T; Hong F; Shao SH; Han K; Dumont D; Slingerland JM
    Mol Cell Biol; 2008 Oct; 28(20):6462-72. PubMed ID: 18710949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Negative regulation of TSC1-TSC2 by mammalian D-type cyclins.
    Zacharek SJ; Xiong Y; Shumway SD
    Cancer Res; 2005 Dec; 65(24):11354-60. PubMed ID: 16357142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dihydroartemisinin inhibits the growth and invasion of gastric cancer cells by regulating cyclin D1-CDK4-Rb signaling.
    Fan HN; Zhu MY; Peng SQ; Zhu JS; Zhang J; Qu GQ
    Pathol Res Pract; 2020 Feb; 216(2):152795. PubMed ID: 31879047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin D1 promotes cell cycle progression through enhancing NDR1/2 kinase activity independent of cyclin-dependent kinase 4.
    Du Z; Tong X; Ye X
    J Biol Chem; 2013 Sep; 288(37):26678-87. PubMed ID: 23897809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RN181 is a tumour suppressor in gastric cancer by regulation of the ERK/MAPK-cyclin D1/CDK4 pathway.
    Wang S; Wang X; Gao Y; Peng Y; Dong N; Xie Q; Zhang X; Wu Y; Li M; Li JL
    J Pathol; 2019 Jun; 248(2):204-216. PubMed ID: 30714150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of growth suppression by p107 via direct phosphorylation by cyclin D1/cyclin-dependent kinase 4.
    Leng X; Noble M; Adams PD; Qin J; Harper JW
    Mol Cell Biol; 2002 Apr; 22(7):2242-54. PubMed ID: 11884610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma.
    Ely S; Di Liberto M; Niesvizky R; Baughn LB; Cho HJ; Hatada EN; Knowles DM; Lane J; Chen-Kiang S
    Cancer Res; 2005 Dec; 65(24):11345-53. PubMed ID: 16357141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDK4 protein is degraded by anaphase-promoting complex/cyclosome in mitosis and reaccumulates in early G
    Chen H; Xu X; Wang G; Zhang B; Wang G; Xin G; Liu J; Jiang Q; Zhang H; Zhang C
    J Biol Chem; 2017 Jun; 292(24):10131-10141. PubMed ID: 28446612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
    Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
    Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclic AMP negatively controls c-myc transcription and G1 cell cycle progression in p210 BCR-ABL transformed cells: inhibitory activity exerted through cyclin D1 and cdk4.
    Williamson EA; Burgess GS; Eder P; Litz-Jackson S; Boswell HS
    Leukemia; 1997 Jan; 11(1):73-85. PubMed ID: 9001421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.
    Joshi KS; Rathos MJ; Joshi RD; Sivakumar M; Mascarenhas M; Kamble S; Lal B; Sharma S
    Mol Cancer Ther; 2007 Mar; 6(3):918-25. PubMed ID: 17363486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.